Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) and Mannatech (NASDAQ:MTEX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Profitability
This table compares Enlivex Therapeutics and Mannatech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enlivex Therapeutics | N/A | 248.08% | 206.39% |
| Mannatech | -11.97% | -2,383.34% | -40.24% |
Volatility and Risk
Enlivex Therapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enlivex Therapeutics | N/A | N/A | $1.24 billion | ($8.25) | -0.56 |
| Mannatech | $108.04 million | 0.08 | -$15.21 million | ($6.71) | -0.65 |
Enlivex Therapeutics has higher earnings, but lower revenue than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current recommendations for Enlivex Therapeutics and Mannatech, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enlivex Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| Mannatech | 1 | 0 | 0 | 0 | 1.00 |
Enlivex Therapeutics presently has a consensus price target of $247.50, indicating a potential upside of 5,292.16%. Given Enlivex Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Mannatech.
Institutional & Insider Ownership
1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 47.5% of Mannatech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Enlivex Therapeutics beats Mannatech on 9 of the 13 factors compared between the two stocks.
About Enlivex Therapeutics
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
About Mannatech
Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
